Latest Insider Transactions at Neuro Pace Inc (NPCE)
This section provides a real-time view of insider transactions for Neuro Pace Inc (NPCE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NeuroPace Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NeuroPace Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2025
|
Frank M Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
2,281
+0.39%
|
$22,810
$10.41 P/Share
|
|
Jun 21
2025
|
Joseph Lacob |
BUY
Grant, award, or other acquisition
|
Direct |
1,080
+8.21%
|
$10,800
$10.41 P/Share
|
|
Jun 21
2025
|
Rakhi Kumar |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+8.45%
|
$14,400
$10.41 P/Share
|
|
Jun 21
2025
|
Uri Geiger |
BUY
Grant, award, or other acquisition
|
Direct |
1,140
+8.65%
|
$11,400
$10.41 P/Share
|
|
Jun 20
2025
|
Patrick F. Williams Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,850
+50.0%
|
-
|
|
Jun 03
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,338
-1.53%
|
$17,394
$13.54 P/Share
|
|
Jun 03
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,337
-1.01%
|
$17,381
$13.54 P/Share
|
|
May 27
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-0.41%
|
$4,284
$12.66 P/Share
|
|
May 27
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-0.27%
|
$4,284
$12.66 P/Share
|
|
May 27
2025
|
Joel Becker CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,126
-1.06%
|
$13,512
$12.66 P/Share
|
|
May 20
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,051
-3.36%
|
$51,867
$17.99 P/Share
|
|
May 20
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,051
-2.24%
|
$51,867
$17.99 P/Share
|
|
May 14
2025
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
168,136
-2.49%
|
$2,522,040
$15.89 P/Share
|
|
Apr 22
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
237
-0.17%
|
$2,370
$10.94 P/Share
|
|
Apr 22
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
237
-0.26%
|
$2,370
$10.94 P/Share
|
|
Mar 24
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,700
+11.4%
|
-
|
|
Mar 21
2025
|
Frank M Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
1,975
+0.34%
|
$23,700
$12.02 P/Share
|
|
Mar 21
2025
|
Joseph Lacob |
BUY
Grant, award, or other acquisition
|
Direct |
935
+7.83%
|
$11,220
$12.02 P/Share
|
|
Mar 21
2025
|
Rakhi Kumar |
BUY
Grant, award, or other acquisition
|
Direct |
1,247
+8.1%
|
$14,964
$12.02 P/Share
|
|
Mar 21
2025
|
Uri Geiger |
BUY
Grant, award, or other acquisition
|
Direct |
987
+8.31%
|
$11,844
$12.02 P/Share
|
|
Mar 10
2025
|
Joel Becker CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
58,500
+35.46%
|
-
|
|
Mar 10
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,700
+7.89%
|
-
|
|
Mar 03
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,337
-1.06%
|
$14,707
$11.81 P/Share
|
|
Mar 03
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,337
-1.66%
|
$14,707
$11.81 P/Share
|
|
Feb 27
2025
|
Joel Becker CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,506
-8.59%
|
$54,072
$12.56 P/Share
|
|
Feb 27
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-1.74%
|
$17,160
$12.56 P/Share
|
|
Feb 27
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-1.12%
|
$17,160
$12.56 P/Share
|
|
Feb 21
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
78,334
-48.86%
|
$1,018,342
$13.72 P/Share
|
|
Feb 20
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,405
-7.23%
|
$47,670
$14.23 P/Share
|
|
Feb 20
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,405
-2.6%
|
$47,670
$14.23 P/Share
|
|
Feb 20
2025
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,270,845
-100.0%
|
$47,437,605
$9.4 P/Share
|
|
Jan 30
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
200
-0.23%
|
$3,000
$15.0 P/Share
|
|
Jan 29
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
100
-0.11%
|
$1,500
$15.0 P/Share
|
|
Jan 24
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,200
-3.55%
|
$48,000
$15.01 P/Share
|
|
Jan 22
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
265
-0.56%
|
$3,710
$14.04 P/Share
|
|
Jan 22
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
265
-0.22%
|
$3,710
$14.04 P/Share
|
|
Dec 21
2024
|
Frank M Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
2,059
+0.35%
|
$22,649
$11.53 P/Share
|
|
Dec 21
2024
|
Joseph Lacob |
BUY
Grant, award, or other acquisition
|
Direct |
975
+8.83%
|
$10,725
$11.53 P/Share
|
|
Dec 21
2024
|
Rakhi Kumar |
BUY
Grant, award, or other acquisition
|
Direct |
1,300
+9.15%
|
$14,300
$11.53 P/Share
|
|
Dec 21
2024
|
Uri Geiger |
BUY
Grant, award, or other acquisition
|
Direct |
1,029
+9.41%
|
$11,319
$11.53 P/Share
|
|
Dec 03
2024
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,413
-2.9%
|
$15,543
$11.93 P/Share
|
|
Dec 03
2024
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,334
-1.11%
|
$14,674
$11.93 P/Share
|
|
Nov 20
2024
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,045
-5.88%
|
$27,405
$9.19 P/Share
|
|
Nov 20
2024
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,045
-2.48%
|
$27,405
$9.19 P/Share
|
|
Oct 25
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
223,991
-4.08%
|
$1,119,955
$5.45 P/Share
|
|
Oct 23
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
147
-0.0%
|
$882
$6.02 P/Share
|
|
Oct 22
2024
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
237
-0.46%
|
$1,422
$6.0 P/Share
|
|
Oct 22
2024
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
237
-0.19%
|
$1,422
$6.0 P/Share
|
|
Oct 22
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,082
-0.07%
|
$24,492
$6.09 P/Share
|
|
Oct 21
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,720
-0.07%
|
$22,320
$6.1 P/Share
|